Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives.

BMC microbiology - 9 Dec 2025

Bientz Léa, Boijout Hugo, Grami Raoudha, Guyet Ulysse, Lahouati Marin, Hertzmann Melissande, Marques Antony, Toirot Audrey, Aillerie Sabine, Coulange-Mayonnove Laure, Groppi Alexis, Nikolski Macha, Bébéar Cécile, Dubois Véronique

Abstract excerpt

OBJECTIVES: Ceftolozane/tazobactam is a relevant option for treating multiresistant Pseudomonas aeruginosa, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms underlying resistance in P. aeruginosa isolates after ceftolozane/tazobactam treatment as well as alternative therapeutic options. METHODS: Antimicrobial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to beta-Lactamases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cephalosporins

Share to Drug Resistance, Multiple, Bacterial

Share to Microbial Sensitivity Tests

Share to Pseudomonas aeruginosa

Share to Pseudomonas Infections

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 41361747
DOI: 10.1186/s12866-025-04517-z
PMCID: PMC12801942

Genes

PDC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives.PMID 41361747Read ↗

Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.Semantic proximity Read ↗

In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated PathwaysSemantic proximity Read ↗

Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance MechanismsSemantic proximity Read ↗

Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.Semantic proximity Read ↗

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosaSemantic proximity Read ↗

Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.Semantic proximity Read ↗

Complex pathways to ceftolozane-tazobactam resistance in clinical <i>Pseudomonas aeruginosa</i> isolates: a genomic epidemiology studySemantic proximity Read ↗

Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countriesSemantic proximity Read ↗

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from SwitzerlandSemantic proximity Read ↗

Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producersSemantic proximity Read ↗

Cefiderocol Activity Against ClinicalPseudomonas aeruginosaIsolates Exhibiting Ceftolozane-Tazobactam ResistanceSemantic proximity Read ↗

Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.